Bio-Rad Laboratories, Inc. Class A Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BIO | VCSH | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Fixed Income |
52-Week High | $356.25 | $80.20 |
52-Week Low | $241.71 | $78.41 |
Enterprise Value | $9.18B | — |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →